Please use this identifier to cite or link to this item: https://doi.org/10.1097/JTO.0b013e318227816a
Title: Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
Authors: Salto-Tellez, M. 
Tsao, M.-S.
Shih, J.-Y.
Thongprasert, S.
Lu, S.
Chang, G.-C.
Au, J.S.-K.
Chou, T.-Y.
Lee, J.-S.
Shi, Y.-K.
Radzi, A.
Kang, J.-H.
Kim, S.-W.
Tan, S.-Y.
Yang, J.C.-H.
Keywords: EGFR
NSCLC
Tyrosine kinase inhibitor
Issue Date: Oct-2011
Citation: Salto-Tellez, M., Tsao, M.-S., Shih, J.-Y., Thongprasert, S., Lu, S., Chang, G.-C., Au, J.S.-K., Chou, T.-Y., Lee, J.-S., Shi, Y.-K., Radzi, A., Kang, J.-H., Kim, S.-W., Tan, S.-Y., Yang, J.C.-H. (2011-10). Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach. Journal of Thoracic Oncology 6 (10) : 1663-1669. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e318227816a
Abstract: Background: Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols. Methods: A consensus meeting was held involving expert oncologists, pulmonologists, and pathologists to discuss the current status and variations in EGFR mutation testing of NSCLC across Asia and to recommend a standard clinical and laboratory testing approach for future use. Results: Currently, EGFR mutation tests are only routinely performed in some East Asian countries and medical centers. The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations. To increase the sensitivity and specificity of the EGFR mutation tests, tissue acquisition and pretest sample evaluation are important steps in addition to standardization of the EGFR mutation test methodology. Conclusion: A standardized EGFR mutation testing protocol is an essential step toward realization of personalized medicine in East Asian NSCLC treatment. © 2011 by the International Association for the Study of Lung Cancer.
Source Title: Journal of Thoracic Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/109248
ISSN: 15560864
DOI: 10.1097/JTO.0b013e318227816a
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

31
checked on Oct 12, 2021

WEB OF SCIENCETM
Citations

33
checked on Oct 12, 2021

Page view(s)

116
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.